Acute Myeloid Leukemia News
Blocking early inflammatory and innate immune signaling is a promising therapeutic target in acute myeloid leukemia (AML), as disruptions in these signaling pathways occur early ... Read more
Alvocidib - Acute Myeloid Leukemia News
Jan 27, 2020 · Alvocidib is a potential new treatment for patients with acute myeloid leukemia (AML) that is currently being developed by Tolero Pharmaceuticals. The U.S. Food and Drug Administration previously granted alvocidib orphan drug …
APVO436 - Acute Myeloid Leukemia News
Jan 21, 2020 · APVO436 is an experimental therapy being developed by Aptevo Therapeutics to treat acute myeloid leukemia (AML) and high-grade myelodysplastic syndrome (MDS). A man-made antibody, APVO436 helps the body’s T-cells to target cancer cells in AML and kill them. How does APVO436 work?
Rigosertib Combo Fails to Prolong Survival in Higher-risk ...
Sep 21, 2020 · When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers that often progress to acute myeloid leukemia (AML), a Phase 3 trial has found.
FDA Approves Venclexta Combinations for Newly Diagnosed AML
Oct 22, 2020 · The U.S. Food and Drug Administration (FDA) has granted full approval to Venclexta , in combination with Vidaza (azacitidine), Dacogen (decitabine), or low-dose cytarabine, for treating newly diagnosed adults with acute myeloid leukemia (AML).
OSU Names Leukemia Research Center in Honor of Scientist …
Dec 10, 2020 · Clara D. Bloomfield dedicated her career to finding new treatments for patients with acute myeloid leukemia (AML) and related disorders. To continue the work of its longtime faculty member, Ohio State University (OSU) has named its leukemia research center in honor of the late scientist.
Privacy Policy - Acute Myeloid Leukemia News
We currently operate over thirty (30) disease-specific news websites that provide patients, caregivers, physicians and industry professionals access to comprehensive, disease-specific news coverage, and we are continuing to grow.
AML Trial Testing Mylotarg Plus Venclexta Now Enrolling US …
Nov 16, 2020 · A Phase 1b study testing Mylotarg (gemtuzumab ozogamicin) plus Venclexta (venetoclax) for adults with relapsing or refractory acute myeloid leukemia (AML) is currently enrolling patients. The trial (NCT04070768) is taking place across four clinical sites in the U.S., led by the University of Illinois Cancer Center in Chicago.
Intellia Looking to Bring Its Potential T-cell Therapy for AML into ...
Jun 8, 2020 · Data from early studies suggest that Intellia Therapeutics‘s proprietary CRISPR/Cas9 technology can more effectively generate tumor targeting T-cells than conventional methods, and support testing NTLA-5001, the company’s engineered cell therapy candidate for acute myeloid leukemia (AML), in people.
JSP191 May Better Prepare Older AML Patients for Stem Cell …
Feb 18, 2021 · JSP191, an investigational therapy by Jasper Therapeutics, showed promising efficacy as a conditioning agent to prepare older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for a stem cell transplant.